| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 25 | 2024 | 57 | 5.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 25 | 2024 | 197 | 4.180 |
Why?
|
| Intensive Care Units | 15 | 2016 | 104 | 2.990 |
Why?
|
| Dyspnea | 15 | 2024 | 48 | 2.650 |
Why?
|
| Terminal Care | 18 | 2019 | 40 | 2.580 |
Why?
|
| Critical Care | 16 | 2021 | 71 | 2.370 |
Why?
|
| Family | 11 | 2016 | 111 | 1.710 |
Why?
|
| Humans | 113 | 2024 | 17611 | 1.480 |
Why?
|
| Quality Assurance, Health Care | 11 | 2014 | 169 | 1.130 |
Why?
|
| Quality of Health Care | 11 | 2016 | 326 | 1.090 |
Why?
|
| Quality of Life | 16 | 2024 | 507 | 1.000 |
Why?
|
| Critical Illness | 8 | 2016 | 50 | 0.990 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 318 | 0.990 |
Why?
|
| Comparative Effectiveness Research | 4 | 2013 | 66 | 0.930 |
Why?
|
| Communication | 7 | 2013 | 194 | 0.920 |
Why?
|
| United States | 42 | 2024 | 3956 | 0.880 |
Why?
|
| Death | 3 | 2008 | 10 | 0.800 |
Why?
|
| Pulmonary Emphysema | 6 | 2024 | 11 | 0.780 |
Why?
|
| Patient-Centered Care | 5 | 2020 | 197 | 0.760 |
Why?
|
| Pain | 7 | 2009 | 79 | 0.710 |
Why?
|
| Male | 40 | 2022 | 10008 | 0.690 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2017 | 228 | 0.670 |
Why?
|
| Middle Aged | 35 | 2021 | 7911 | 0.660 |
Why?
|
| Patient Satisfaction | 4 | 2016 | 211 | 0.630 |
Why?
|
| Aged | 28 | 2021 | 6095 | 0.620 |
Why?
|
| Female | 40 | 2022 | 12608 | 0.610 |
Why?
|
| Pulmonary Medicine | 6 | 2016 | 19 | 0.610 |
Why?
|
| Pain Management | 5 | 2009 | 58 | 0.610 |
Why?
|
| Professional-Family Relations | 4 | 2013 | 49 | 0.600 |
Why?
|
| Medical Records | 2 | 2016 | 100 | 0.590 |
Why?
|
| Consensus | 4 | 2024 | 41 | 0.570 |
Why?
|
| Antiviral Agents | 3 | 2022 | 94 | 0.560 |
Why?
|
| Guideline Adherence | 5 | 2019 | 155 | 0.550 |
Why?
|
| Quality Indicators, Health Care | 7 | 2010 | 181 | 0.540 |
Why?
|
| Terminally Ill | 3 | 2013 | 8 | 0.540 |
Why?
|
| Analgesics, Opioid | 4 | 2015 | 243 | 0.520 |
Why?
|
| Societies, Medical | 10 | 2024 | 74 | 0.520 |
Why?
|
| Multiple Chronic Conditions | 4 | 2019 | 25 | 0.510 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 13 | 0.510 |
Why?
|
| Patient Care Team | 7 | 2012 | 113 | 0.500 |
Why?
|
| Attitude to Death | 2 | 2005 | 5 | 0.500 |
Why?
|
| Treatment Outcome | 14 | 2024 | 1259 | 0.480 |
Why?
|
| Disease Progression | 4 | 2021 | 264 | 0.470 |
Why?
|
| Adult | 23 | 2023 | 7598 | 0.460 |
Why?
|
| Disease Management | 5 | 2016 | 135 | 0.460 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 454 | 0.460 |
Why?
|
| Music Therapy | 1 | 2013 | 1 | 0.450 |
Why?
|
| Asthma | 4 | 2012 | 385 | 0.440 |
Why?
|
| Surveys and Questionnaires | 11 | 2020 | 1309 | 0.430 |
Why?
|
| Nursing Staff, Hospital | 1 | 2012 | 11 | 0.420 |
Why?
|
| Nurse's Role | 1 | 2012 | 7 | 0.420 |
Why?
|
| Perioperative Care | 1 | 2012 | 4 | 0.400 |
Why?
|
| Process Assessment (Health Care) | 1 | 2012 | 24 | 0.390 |
Why?
|
| Evidence-Based Medicine | 6 | 2021 | 185 | 0.390 |
Why?
|
| Pharmacists | 1 | 2012 | 48 | 0.390 |
Why?
|
| Blood Pressure | 2 | 2019 | 298 | 0.390 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 4 | 0.380 |
Why?
|
| Alanine | 2 | 2021 | 6 | 0.380 |
Why?
|
| Hypoglycemia | 1 | 2012 | 46 | 0.380 |
Why?
|
| Referral and Consultation | 4 | 2024 | 167 | 0.380 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 415 | 0.370 |
Why?
|
| Withholding Treatment | 6 | 2019 | 26 | 0.370 |
Why?
|
| Electronic Health Records | 6 | 2021 | 681 | 0.370 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 1900 | 0.370 |
Why?
|
| Smoking Cessation | 4 | 2016 | 193 | 0.360 |
Why?
|
| Home Care Services | 2 | 2021 | 22 | 0.360 |
Why?
|
| Advance Care Planning | 5 | 2022 | 12 | 0.350 |
Why?
|
| Lung | 3 | 2019 | 62 | 0.350 |
Why?
|
| Pneumoperitoneum | 2 | 2000 | 2 | 0.340 |
Why?
|
| Relaxation Therapy | 1 | 2009 | 5 | 0.340 |
Why?
|
| Breathing Exercises | 1 | 2009 | 2 | 0.340 |
Why?
|
| Sleep Medicine Specialty | 3 | 2016 | 5 | 0.340 |
Why?
|
| Smoking | 4 | 2017 | 483 | 0.340 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 130 | 0.340 |
Why?
|
| Meditation | 1 | 2009 | 20 | 0.340 |
Why?
|
| Delphi Technique | 3 | 2024 | 33 | 0.340 |
Why?
|
| Patient Preference | 2 | 2020 | 48 | 0.340 |
Why?
|
| Risk Assessment | 6 | 2020 | 1097 | 0.330 |
Why?
|
| Attitude of Health Personnel | 5 | 2019 | 212 | 0.330 |
Why?
|
| Internet | 3 | 2023 | 231 | 0.320 |
Why?
|
| Family Relations | 1 | 2008 | 16 | 0.320 |
Why?
|
| Lung Diseases | 5 | 2016 | 42 | 0.310 |
Why?
|
| Sleep Wake Disorders | 3 | 2017 | 37 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 322 | 0.300 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 255 | 0.300 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 2 | 0.300 |
Why?
|
| Continuity of Patient Care | 6 | 2022 | 105 | 0.290 |
Why?
|
| Eligibility Determination | 1 | 2006 | 12 | 0.280 |
Why?
|
| Caregivers | 5 | 2020 | 127 | 0.280 |
Why?
|
| Retrospective Studies | 12 | 2021 | 2447 | 0.270 |
Why?
|
| Patient Admission | 1 | 2006 | 72 | 0.270 |
Why?
|
| Hospice Care | 3 | 2019 | 8 | 0.270 |
Why?
|
| Niacin | 1 | 2006 | 3 | 0.260 |
Why?
|
| Hypotension | 1 | 2006 | 5 | 0.260 |
Why?
|
| Self Medication | 1 | 2006 | 5 | 0.260 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 40 | 0.260 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 37 | 0.260 |
Why?
|
| Health Care Costs | 3 | 2019 | 228 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 205 | 0.250 |
Why?
|
| Antipsychotic Agents | 1 | 2006 | 49 | 0.250 |
Why?
|
| Hypertension | 2 | 2019 | 500 | 0.240 |
Why?
|
| Respiratory Distress Syndrome, Adult | 2 | 2019 | 9 | 0.240 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 12 | 0.230 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 1322 | 0.230 |
Why?
|
| Translational Medical Research | 2 | 2016 | 35 | 0.230 |
Why?
|
| Emphysema | 1 | 2024 | 1 | 0.230 |
Why?
|
| Biomedical Research | 2 | 2024 | 86 | 0.230 |
Why?
|
| Double-Blind Method | 5 | 2022 | 155 | 0.230 |
Why?
|
| Outcome and Process Assessment (Health Care) | 4 | 2014 | 102 | 0.230 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 14 | 0.220 |
Why?
|
| Curriculum | 2 | 2015 | 35 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 250 | 0.210 |
Why?
|
| Patient Participation | 2 | 2020 | 133 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2022 | 19 | 0.210 |
Why?
|
| Clinical Competence | 4 | 2015 | 99 | 0.210 |
Why?
|
| Psychotherapy, Group | 1 | 2022 | 26 | 0.210 |
Why?
|
| Heart Diseases | 2 | 2015 | 77 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 42 | 0.200 |
Why?
|
| Mindfulness | 1 | 2022 | 27 | 0.200 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2019 | 11 | 0.200 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 1 | 0.200 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 4 | 0.200 |
Why?
|
| Observation | 2 | 2012 | 23 | 0.200 |
Why?
|
| Focus Groups | 3 | 2020 | 147 | 0.190 |
Why?
|
| Ambulatory Care | 3 | 2016 | 244 | 0.190 |
Why?
|
| Neoplasms | 5 | 2009 | 438 | 0.190 |
Why?
|
| Thoracic Diseases | 1 | 2021 | 2 | 0.190 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2021 | 3 | 0.190 |
Why?
|
| Azetidines | 1 | 2020 | 2 | 0.190 |
Why?
|
| Purines | 1 | 2020 | 3 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2020 | 3 | 0.190 |
Why?
|
| Information Systems | 1 | 2021 | 22 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2020 | 14 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 34 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 47 | 0.180 |
Why?
|
| Decision Making | 2 | 2019 | 183 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2023 | 1267 | 0.180 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2020 | 33 | 0.180 |
Why?
|
| Bronchoscopy | 2 | 2024 | 8 | 0.180 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 21 | 0.180 |
Why?
|
| Life Support Care | 2 | 2012 | 4 | 0.170 |
Why?
|
| Watchful Waiting | 1 | 2019 | 18 | 0.170 |
Why?
|
| Forced Expiratory Volume | 4 | 2024 | 69 | 0.170 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2020 | 12 | 0.170 |
Why?
|
| Health Personnel | 1 | 2001 | 124 | 0.170 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2019 | 6 | 0.170 |
Why?
|
| House Calls | 1 | 2019 | 11 | 0.170 |
Why?
|
| Oregon | 3 | 2019 | 171 | 0.170 |
Why?
|
| Respiratory Function Tests | 2 | 2016 | 32 | 0.170 |
Why?
|
| Comorbidity | 2 | 2024 | 594 | 0.160 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 24 | 0.160 |
Why?
|
| Analgesia | 3 | 2009 | 4 | 0.160 |
Why?
|
| Acute Disease | 3 | 2015 | 142 | 0.160 |
Why?
|
| Patient Care Management | 2 | 2012 | 30 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 598 | 0.160 |
Why?
|
| Metformin | 1 | 2019 | 57 | 0.160 |
Why?
|
| Interviews as Topic | 2 | 2012 | 305 | 0.160 |
Why?
|
| Patient Care Planning | 2 | 2013 | 52 | 0.160 |
Why?
|
| Pneumonectomy | 2 | 2015 | 7 | 0.160 |
Why?
|
| Self Report | 1 | 2020 | 251 | 0.150 |
Why?
|
| Insulin | 1 | 2019 | 205 | 0.150 |
Why?
|
| Spirometry | 4 | 2021 | 65 | 0.150 |
Why?
|
| Culture | 2 | 2009 | 25 | 0.150 |
Why?
|
| Hospital Mortality | 2 | 2020 | 145 | 0.150 |
Why?
|
| Organizational Policy | 3 | 2016 | 12 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 531 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2016 | 68 | 0.140 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 7 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 28 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2021 | 2570 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 11 | 0.140 |
Why?
|
| Smokers | 1 | 2016 | 12 | 0.140 |
Why?
|
| Bronchi | 2 | 2019 | 2 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 268 | 0.140 |
Why?
|
| Intention | 1 | 2016 | 28 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 29 | 0.130 |
Why?
|
| Nurses | 1 | 2016 | 36 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2020 | 297 | 0.130 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 19 | 0.130 |
Why?
|
| Inpatients | 2 | 2016 | 81 | 0.130 |
Why?
|
| Research Report | 1 | 2015 | 22 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 18 | 0.130 |
Why?
|
| Hospitalists | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2015 | 2 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 568 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 489 | 0.120 |
Why?
|
| Research Design | 3 | 2013 | 374 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2016 | 110 | 0.120 |
Why?
|
| Health Promotion | 2 | 2015 | 280 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2016 | 298 | 0.120 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2014 | 4 | 0.120 |
Why?
|
| Administration, Inhalation | 3 | 2021 | 37 | 0.120 |
Why?
|
| Hospitals | 3 | 2021 | 80 | 0.120 |
Why?
|
| Patient Care | 1 | 2014 | 35 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 85 | 0.110 |
Why?
|
| Young Adult | 4 | 2013 | 2427 | 0.110 |
Why?
|
| Guidelines as Topic | 2 | 2006 | 40 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 471 | 0.110 |
Why?
|
| Sleep | 2 | 2014 | 58 | 0.110 |
Why?
|
| California | 2 | 2019 | 2284 | 0.110 |
Why?
|
| Nurse-Patient Relations | 1 | 2012 | 8 | 0.110 |
Why?
|
| Patient Selection | 2 | 2004 | 190 | 0.100 |
Why?
|
| Time Factors | 4 | 2020 | 1086 | 0.100 |
Why?
|
| Smoking Prevention | 1 | 2012 | 54 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2012 | 38 | 0.100 |
Why?
|
| Professional Role | 1 | 2012 | 10 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 16 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2013 | 189 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2008 | 102 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2012 | 85 | 0.100 |
Why?
|
| Hospitalization | 2 | 2020 | 797 | 0.100 |
Why?
|
| Psychometrics | 2 | 2014 | 121 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 748 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2012 | 254 | 0.100 |
Why?
|
| Pleural Diseases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2011 | 1 | 0.090 |
Why?
|
| Respiratory Tract Fistula | 1 | 2011 | 1 | 0.090 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 2 | 0.090 |
Why?
|
| Length of Stay | 1 | 2012 | 181 | 0.090 |
Why?
|
| Pediatrics | 1 | 2012 | 158 | 0.090 |
Why?
|
| Health Services Research | 2 | 2009 | 231 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2010 | 31 | 0.090 |
Why?
|
| Reimbursement, Incentive | 1 | 2010 | 27 | 0.090 |
Why?
|
| Wakefulness | 1 | 2009 | 1 | 0.090 |
Why?
|
| Respiration | 1 | 2009 | 8 | 0.090 |
Why?
|
| Laparotomy | 2 | 2000 | 3 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 114 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2009 | 20 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2012 | 341 | 0.080 |
Why?
|
| Pain, Intractable | 1 | 2009 | 1 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2009 | 5 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 159 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 85 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 47 | 0.080 |
Why?
|
| Podiatry | 1 | 2008 | 2 | 0.080 |
Why?
|
| Foot | 1 | 2008 | 3 | 0.080 |
Why?
|
| Walking | 1 | 2009 | 85 | 0.080 |
Why?
|
| Data Collection | 2 | 2012 | 256 | 0.080 |
Why?
|
| Models, Organizational | 2 | 2009 | 55 | 0.080 |
Why?
|
| African Americans | 2 | 2016 | 472 | 0.080 |
Why?
|
| Continental Population Groups | 1 | 2010 | 302 | 0.080 |
Why?
|
| Logistic Models | 3 | 2017 | 926 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 17 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2009 | 141 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 52 | 0.080 |
Why?
|
| Enteral Nutrition | 2 | 1999 | 6 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 358 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2016 | 309 | 0.070 |
Why?
|
| Vital Capacity | 2 | 2017 | 35 | 0.070 |
Why?
|
| Family Health | 1 | 2007 | 44 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 1210 | 0.070 |
Why?
|
| Body Temperature | 1 | 2006 | 4 | 0.070 |
Why?
|
| Analgesics | 1 | 2006 | 27 | 0.070 |
Why?
|
| Urban Population | 1 | 2006 | 116 | 0.070 |
Why?
|
| Needs Assessment | 2 | 2009 | 66 | 0.070 |
Why?
|
| Outpatients | 2 | 2020 | 107 | 0.070 |
Why?
|
| Health Surveys | 1 | 2006 | 260 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2006 | 85 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2006 | 77 | 0.060 |
Why?
|
| Canada | 2 | 2015 | 66 | 0.060 |
Why?
|
| Adolescent | 4 | 2012 | 3651 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 186 | 0.060 |
Why?
|
| Drug Overdose | 1 | 2006 | 56 | 0.060 |
Why?
|
| Progressive Patient Care | 1 | 2004 | 1 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 18 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2023 | 1409 | 0.060 |
Why?
|
| Computer Security | 1 | 2014 | 5 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 630 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 98 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 231 | 0.060 |
Why?
|
| Patient Discharge | 2 | 2012 | 154 | 0.060 |
Why?
|
| Geriatric Nursing | 1 | 2003 | 3 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 3 | 0.050 |
Why?
|
| Resource Allocation | 1 | 2022 | 5 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 12 | 0.050 |
Why?
|
| Triage | 1 | 2022 | 15 | 0.050 |
Why?
|
| Injection Site Reaction | 1 | 2022 | 1 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 233 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2022 | 12 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 18 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 59 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 64 | 0.050 |
Why?
|
| Child | 2 | 2023 | 2474 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 3 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 4 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 14 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 19 | 0.050 |
Why?
|
| Oxygen | 1 | 2021 | 16 | 0.050 |
Why?
|
| Dry Powder Inhalers | 1 | 2021 | 1 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2021 | 21 | 0.050 |
Why?
|
| Ethics, Professional | 1 | 2001 | 1 | 0.050 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 1 | 0.050 |
Why?
|
| Organizational Objectives | 1 | 2001 | 18 | 0.050 |
Why?
|
| Teaching | 1 | 2001 | 14 | 0.050 |
Why?
|
| Radiologists | 1 | 2020 | 4 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2020 | 26 | 0.050 |
Why?
|
| Program Development | 1 | 2001 | 69 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 2000 | 7 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Inhalation | 1 | 2019 | 1 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 15 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 844 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 86 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 1171 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 91 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 215 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 57 | 0.040 |
Why?
|
| Raynaud Disease | 1 | 1999 | 1 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1999 | 2 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 1999 | 7 | 0.040 |
Why?
|
| Radiography | 1 | 1999 | 39 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 1999 | 17 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 181 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 1999 | 30 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 26 | 0.040 |
Why?
|
| Prostatectomy | 1 | 1999 | 75 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 325 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 150 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 374 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 140 | 0.040 |
Why?
|
| Depression | 3 | 2008 | 502 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 161 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 635 | 0.040 |
Why?
|
| Prevalence | 1 | 2000 | 884 | 0.040 |
Why?
|
| Femoral Nerve | 1 | 1997 | 1 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 1 | 1997 | 1 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 1997 | 1 | 0.040 |
Why?
|
| Abdomen | 1 | 1997 | 20 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 1997 | 8 | 0.040 |
Why?
|
| Social Support | 2 | 2009 | 203 | 0.040 |
Why?
|
| Metered Dose Inhalers | 1 | 2016 | 5 | 0.040 |
Why?
|
| Self Administration | 1 | 2016 | 9 | 0.040 |
Why?
|
| Advance Directives | 2 | 2008 | 6 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2016 | 12 | 0.030 |
Why?
|
| Northwestern United States | 1 | 2016 | 53 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 22 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 42 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2016 | 2 | 0.030 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 5 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 39 | 0.030 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2016 | 6 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 33 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 200 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 77 | 0.030 |
Why?
|
| Respiratory Therapy | 1 | 2016 | 1 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 47 | 0.030 |
Why?
|
| Jejunostomy | 1 | 1995 | 1 | 0.030 |
Why?
|
| Pneumonia, Aspiration | 1 | 1995 | 2 | 0.030 |
Why?
|
| Gastrostomy | 1 | 1995 | 3 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 10 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 3325 | 0.030 |
Why?
|
| Research | 1 | 2016 | 64 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 304 | 0.030 |
Why?
|
| Brain Death | 1 | 2014 | 1 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Informed Consent | 1 | 2014 | 19 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 671 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 7 | 0.030 |
Why?
|
| Angiography | 1 | 2014 | 12 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 260 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 8 | 0.030 |
Why?
|
| Social Behavior | 1 | 2014 | 23 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 70 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 34 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 85 | 0.030 |
Why?
|
| Controlled Before-After Studies | 1 | 2013 | 4 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 8 | 0.030 |
Why?
|
| Checklist | 1 | 2013 | 15 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 44 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 917 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2012 | 13 | 0.030 |
Why?
|
| Mental Health | 1 | 2014 | 165 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 16 | 0.030 |
Why?
|
| Cost Savings | 1 | 2012 | 23 | 0.030 |
Why?
|
| Automation | 1 | 2012 | 24 | 0.030 |
Why?
|
| Benchmarking | 1 | 2012 | 46 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.020 |
Why?
|
| Telephone | 1 | 2012 | 161 | 0.020 |
Why?
|
| Canes | 1 | 2011 | 1 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 2011 | 1 | 0.020 |
Why?
|
| Compassionate Use Trials | 1 | 2011 | 1 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 8 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 137 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 189 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 30 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 643 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 25 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2010 | 23 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 230 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 428 | 0.020 |
Why?
|
| Public Health | 1 | 2010 | 80 | 0.020 |
Why?
|
| Proxy | 1 | 2009 | 4 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2010 | 146 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 145 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 501 | 0.020 |
Why?
|
| Health Policy | 1 | 2009 | 122 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 223 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 201 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2010 | 485 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 330 | 0.020 |
Why?
|
| Religion | 1 | 2005 | 14 | 0.020 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2005 | 1 | 0.020 |
Why?
|
| Social Class | 1 | 2005 | 120 | 0.020 |
Why?
|